This article is more than 5 years old. Information may no longer be current.

Allergan reports 33% increased Q2 net sales

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

IRVINE, Calif. — Allergan Inc. reported second quarter net product sales increased 33.2% over the second quarter 2005 to total $787 million, which includes $128.3 million of net sales acquired in its acquisition of Inamed, according to a press release.

Excluding products acquired in the Inamed acquisition, pharmaceutical sales increased 16% compared with the second quarter 2005.

For the quarter, eye care pharmaceutical sales increased 16.7% over the second quarter 2005 to $379.2 million, with sales of Botox (botulinum toxin type A) increasing 16.9% to $248.4 million. Sales of Lumigan (bimatoprost ophthalmic solution) increased 32.7% to $81.7 million. Sales of its Alphagan (brimonidine tartrate ophthalmic solution) family of products increased 9.2% to $70.2 million, and sales of Restasis (cyclosporine ophthalmic emulsion) increased 41.8% over the second quarter 2005 to $65.6 million.

The company reported diluted earnings per share of $0.49, a 96% increase over per share earnings of $0.25 for the second quarter of 2005.

It also announced that its board of directors has declared a second quarter dividend of $0.10 per share, payable on Sept. 12, 2006 to stockholders of record on Aug. 18, 2006, according to the release.